The evidence currently available suggests that linezolid is as effective as any other antibiotic for most indications it was studied for. Its main application is in severe vancomycin-resistant Cocci Gram-positive infections, especially in the treatment of vancomycin-resistant enterococci (VRE). Even though there are studies suggesting that linezolid is more effective than vancomycin in staphylococcal infections, the application of these results is controversial due to some methodological issues. The concern about the emergence of resistance makes it reasonable to limit its use to those cases where no response to vancomycin is obtained, with suspected or confirmed etiology due to MRSA, particularly in nosocomial pneumonia, ventilator-associated pneumonia and skin/soft tissue infections in adult and pediatric patients.